{"analyses":[{"ciLowerLimit":"0.471","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.913","estimateComment":"Hazard ratio was estimated by Cox proportional hazards model","groupDescription":"Stratified Analysis; Stratification factors: Prior exposure to proteasome inhibitors (naïve versus sensitive), and number of prior lines of therapy (1 versus 2 or 3)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.012","paramType":"Hazard Ratio (HR)","paramValue":"0.656","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.3","upperLimit":"27.5","value":"23.2"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"15.0","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"PFS is defined as the number of days from the date the participant was randomized to the date of the first documented progressive disease (PD) as determined by an Independent Review Committee (IRC) or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization","reportingStatus":"POSTED","timeFrame":"Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}